Skip to content

Optimization and verification of malignant risk prediction model for pulmonary nodules: a prospective cohort study

Optimization and verification of malignant risk prediction model for pulmonary nodules: a prospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022893
Enrollment
Unknown
Registered
2019-04-30
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Pulmonary Nodule

Interventions

Gold Standard:Pathological examination
Index test:mature&#32
predictive&#32
model&#32
of&#32
risk&#32

Sponsors

Cancer Hospital Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 74 Years

Inclusion criteria

Inclusion criteria: This study is Project 3 of National Key R&D Program of China (i.e. "Lung and colorectal cancer screening: a population-based multicenter randomized controlled trial"). Thirty thousand participants will go LDCT screening in Project 1 (registration No: ChiCTR1900021588).Based on Project 1, those who are diagnosed with suspected pulmonary nodules ( about 2,500) will be invited to participate in this study.(Suspected pulmonary nodules refer to solid or partially solid nodules =5 mm in diameter, non-solid nodules =8 mm in diameter, and whose imaging findings favor lung cancer)

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Sensitivity;Specificity;Negative Predictive Value;Positive Predictive Value;Area Under the Curve;Net Reclassification Improvement;Integrated Discrimination Improvement;

Secondary

MeasureTime frame
Proportion of Lung Cancer;

Countries

China

Contacts

Public ContactFengwei Tan

Cancer Hospital Chinese Academy of Medical Sciences

tanfengwei@126.com+86 10 87788798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026